Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation study of subretinal VG801 for ABCA4 biallelic mutation-associated retinal dystrophy
CTR20261929Phase 2Active
- Sponsor
- 德康明基医疗科技
- Start
- Jul 2026
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Engineered AAV → AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VG801 in Fundus dystrophy, ABCA4 retinopathy (ABCA4R), sponsored by 德康明基医疗科技. Started Jul 2026; status: active.
02
Drugs
VG801
03
Conditions
Fundus dystrophyABCA4 retinopathy (ABCA4R)
Beyond the preview
Go deeper on CTR20261929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261929.